BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31944444)

  • 1. Definitive chemoradiotherapy for cervical cancer: A 11-year population-based study.
    Kalampokas E; Macdonald G; Young H; Bednarek A; Kennedy AM; Cairns M; Parkin DE
    Eur J Cancer Care (Engl); 2020 May; 29(3):e13223. PubMed ID: 31944444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam.
    Phung HT; Truong MC; Nguyen LT; Dang ATV; Vu TH; Nguyen HT
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):853-859. PubMed ID: 33773550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
    Teh J; Yap SP; Tham I; Sethi VK; Chua EJ; Yeo R; Ho TH; Tay EH; Chia YN; Soh LT; Khoo-Tan HS
    Int J Gynecol Cancer; 2010 Apr; 20(3):428-33. PubMed ID: 20375809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological Risk Factors and Outcomes in Women With Stage IB2 Cervical Cancer Treated With Primary Radical Surgery Versus Chemoradiotherapy.
    Bradbury M; Founta C; Taylor W; Kucukmetin A; Naik R; Ang C
    Int J Gynecol Cancer; 2015 Oct; 25(8):1476-83. PubMed ID: 26244756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of postoperative simple chemotherapy and concurrent chemoradiotherapy in FIGO stage IB2-IIB cervical cancer].
    Ma K; Yang YH; Yang X; Feng ZY; Liu TY; Wen HW; Liao QP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 45(6):910-5. PubMed ID: 24343073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.
    Ho JC; Allen PK; Bhosale PR; Rauch GM; Fuller CD; Mohamed AS; Frumovitz M; Jhingran A; Klopp AH
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):546-553. PubMed ID: 28011045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
    Shrivastava S; Mahantshetty U; Engineer R; Chopra S; Hawaldar R; Hande V; Kerkar RA; Maheshwari A; Shylasree TS; Ghosh J; Bajpai J; Gurram L; Gulia S; Gupta S;
    JAMA Oncol; 2018 Apr; 4(4):506-513. PubMed ID: 29423520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.
    Brodeur MN; Dejean R; Beauchemin MC; Samouëlian V; Cormier B; Bacha OM; Warkus T; Barkati M
    Gynecol Oncol; 2021 Aug; 162(2):277-283. PubMed ID: 34059350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.
    Castelnau-Marchand P; Chargari C; Maroun P; Dumas I; Del Campo ER; Cao K; Petit C; Martinetti F; Tafo-Guemnie A; Lefkopoulos D; Morice P; Haie-Meder C; Mazeron R
    Gynecol Oncol; 2015 Nov; 139(2):288-94. PubMed ID: 26364808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
    Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
    Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
    Monnier L; Touboul E; Daraï E; Lefranc JP; Lauratet B; Ballester M; Huguet F
    Bull Cancer; 2016 Feb; 103(2):164-72. PubMed ID: 26822905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
    Hu K; Wang W; Liu X; Meng Q; Zhang F
    Radiat Oncol; 2018 Dec; 13(1):249. PubMed ID: 30558636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
    Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended field radiotherapy with or without chemotherapy in patients with cervical cancer and positive para-aortic lymph nodes: a single institution retrospective review.
    Ng BH; Rozita A; Adlinda A; Lee WC; Wan Zamaniah W
    Asian Pac J Cancer Prev; 2015; 16(9):3827-33. PubMed ID: 25987044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
    Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
    Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.